1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Aug 2025
Admin
News Article

Bio-Thera and STADA Expand Biosimilars Alliance to Tocilizumab

The biosimilars race in Europe just got a major boost. Bio-Thera Solutions and STADA Arzneimittel have extended their partnership to include tocilizumab, a blockbuster immunosuppressant used to treat multiple inflammatory conditions.

What’s New

Bio-Thera will handle development, manufacturing, and supply of the biosimilar to Roche’s RoActemra®.
STADA will get exclusive commercialization rights across the EU, UK, Switzerland, and select markets.
The deal builds on their May 2024 alliance around BAT2506 (golimumab biosimilar to Simponi®), which already has a marketing application under EMA review.

This extension is subject to shareholder approval, but both companies see it as a natural progression.

Why It Matters

Market size: RoActemra/Actemra pulled in €2.8 billion in 2024, including ~$700 million from Europe alone—even with biosimilar competition starting.
Patient access: Biosimilars like this lower costs, increase availability, and expand treatment options for patients with arthritis and other autoimmune conditions.
Strategic scale: For STADA, tocilizumab strengthens its immunology franchise alongside adalimumab and ustekinumab biosimilars, which already lead in several European markets.

Voices from Leadership

“STADA is a proven leader in biosimilars. Extending our partnership ensures patients across Europe gain access to affordable tocilizumab,” said Dr. Shengfeng Li, CEO of Bio-Thera.
“With €2.8 billion in global sales, tocilizumab is a major opportunity to broaden access and build scale in immunology,” added Ian Henshaw, STADA’s head of global specialty.

Recent Milestones

In June 2024, Bio-Thera’s BAT1806 (tocilizumab biosimilar) received EU-wide marketing authorization for 20mg/ml vials.
This approval followed a positive EMA opinion for treating multiple arthritic conditions.

The Bigger Picture

This partnership underscores how China-based innovators (Bio-Thera) and European commercialization specialists (STADA) are teaming up to challenge branded biologics head-on.

For patients, it means faster, wider access to high-quality biosimilars. For pharma, it signals the continued erosion of originator monopolies in immunology.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!